Pecten oculi

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Retrieved on: 
Wednesday, November 15, 2023
NDA, Dexamethasone, Safety, PSME, Business analyst, Telecanthus, Visual acuity, DED, CME, International, AON, IND, Investment, Uveitis, Bank statement, Net, Patient, Research, DME, Week, Hierarchy, Inflammation, Genotype, Pain, UME, Stage 2, SNP, TNF, CHF, POC, CST, International Financial Reporting Standards, OCS, Pharmaceutical industry, Life insurance, Pecten oculi, Ophthalmology

ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.

Key Points: 
  • ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.
  • Oculis anticipates first patient enrollment toward the end of 2023 and beginning of 2024 in all three pivotal trials.
  • Oculis is on track to deliver the first patient first visit before the end of 2023 with clinical data readout expected in mid-2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Retrieved on: 
Monday, September 11, 2023
Retina, Senior, Marketing, OCS, MIT, Inflammation, Princeton University, McKinsey & Company, Pain, Bausch & Lomb, Telecanthus, Neuroscience, Novartis, Alcon, Patient, Ophthalmology, Management, Pharmaceutical industry, Idorsia, Pecten oculi

In this key role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally, and building the required commercial infrastructure to bring all of Oculis’ groundbreaking ophthalmic product candidates to markets worldwide.

Key Points: 
  • In this key role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally, and building the required commercial infrastructure to bring all of Oculis’ groundbreaking ophthalmic product candidates to markets worldwide.
  • Riad Sherif, M.D., Chief Executive Officer of Oculis: “We are thrilled to have Rebecca join us at Oculis.
  • With her significant commercial leadership experience in ophthalmology spanning global strategy, marketing, and market access and her solid US market knowledge, Rebecca is the perfect fit for this role especially as Oculis initiates preparation of its anticipated first US launch with OCS-01.
  • She received her Ph.D. in political science from Massachusetts Institute of Technology (MIT) and holds a B.A.

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 29, 2023
Knowledge, DME, Week, Cerebral edema, Economics, Pain, Telecanthus, Acquisition, Investment, Patient, International Financial Reporting Standards, OCT, Macular edema, Disease, Maintenance, Hierarchy, OCS, Research, Diabetic retinopathy, Stanford University School of Medicine, PSME, CST, Uveitis, Paratriathlon, IND, Safety, Human, POC, International, Icelandic Association for Search and Rescue, Business, SNP, Master of Science, CHF, CME, DED, Genotype, TNF, AON, Bank statement, NDA, Inflammation, Dexamethasone, European Inventor Award, Visual acuity, UME, Pharmaceutical industry, Medical imaging, Cryptocurrency, Ophthalmology, MD, Pecten oculi

Riad Sherif MD, Chief Executive Officer of Oculis: “This has been a very exciting period for Oculis.

Key Points: 
  • Riad Sherif MD, Chief Executive Officer of Oculis: “This has been a very exciting period for Oculis.
  • Reported positive topline results in August 2023 from Phase 3 OPTIMIZE trial of OCS-01 in treating inflammation and pain following ocular surgery.
  • Both trials concluded in 2023 and achieved positive topline results as announced in May and August of 2023.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Oculis Announces to Present at Upcoming August Investor Conferences

Retrieved on: 
Wednesday, July 26, 2023
Pecten oculi, Event, Financial adviser

The Oculis management team will be available for one-on-one meetings during the conferences.

Key Points: 
  • The Oculis management team will be available for one-on-one meetings during the conferences.
  • Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
  • Links to access company presentation for select events, when available, will be posted to Oculis’s website on the Events & Presentations page of the Investors section.

Oculis to Present at OIS Retina Innovation Summit

Retrieved on: 
Wednesday, July 19, 2023
Diabetic retinopathy, Ophthalmology, OCS, DME, Pharmaceutical industry, Pecten oculi, MD

ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, CEO of Oculis, will participate at OIS Retina Innovation Summit , an event organized by Ophthalmology Innovation Source, on July 27, in Seattle, Washington.

Key Points: 
  • ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, CEO of Oculis, will participate at OIS Retina Innovation Summit , an event organized by Ophthalmology Innovation Source, on July 27, in Seattle, Washington.
  • In addition to participating, Dr. Sherif will present an update on Oculis with a focus on the recently announced positive DIAMOND Phase 3 Stage 1 readout of OCS-01 eye drops for the treatment of Diabetic Macular Edema (DME) and associated next steps.

Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023

Retrieved on: 
Monday, June 26, 2023
University of Southern California, DME, Stanford University, Partner (business rank), Teaching hospital, Alcon, Lotte New York Palace Hotel, SAB, University, Neuroscience, OCS, Genentech, Stanford University School of Medicine, Retina, POC, Keck School of Medicine of USC, Neuro-ophthalmology, Master of Science, Clinical research, Webcast, CME, Drug development, University of Paris, Q&A, AON, University of Nevada, Reno School of Medicine, Diabetic retinopathy, Reno 1868 FC, Neuro, Medical director, Novartis, Fellow, USC Eye Institute, Tourism, Pharmaceutical industry, Management, Development, Ophthalmology, MD, Pecten oculi, Medicine

ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.

Key Points: 
  • ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.
  • Those interested can participate in the event either in-person at the Lotte New York Palace Hotel, or virtually via webcast.
  • To register for the event, please click here .
  • The additional expert panelists participating in the Q&A session include:
    Pravin Dugel, MD: Oculis Board of Directors member, retina specialist, and President of Iveric Bio.

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Retrieved on: 
Thursday, June 1, 2023
DME, SHP, DR, OCS, Diabetic retinopathy, Unity Biotechnology, VEGF, Pharmaceutical industry, Telescopic sight, Pecten oculi

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME).

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME).
  • The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field.
  • This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in diabetic eye disease, providing valuable insights for investors and companies.
  • Based on interviews and analysis with dozens of companies and KOLs, this report offers an important resource for anyone seeking an understanding of diabetic eye disease treatment.

Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

Retrieved on: 
Thursday, June 1, 2023
Attention, Diabetic retinopathy, Telephone, BofA Securities, Secure Federal File Sharing Act, OCS, Arctica Finance, Sale, Prospectus, State Street, SVB, Form, Pecten oculi, SVB Securities, Pareto, Life insurance

ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the pricing of a follow-on public offering of 3,500,000 ordinary shares at a public offering price of $11.50 per ordinary share, for gross proceeds of $40.25 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the pricing of a follow-on public offering of 3,500,000 ordinary shares at a public offering price of $11.50 per ordinary share, for gross proceeds of $40.25 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, Oculis has granted the underwriters a 30-day option to purchase up to an additional 525,000 ordinary shares on the same terms and conditions.
  • The offering is expected to close on or about June 5, 2023, subject to satisfaction of customary closing conditions.
  • BofA Securities and SVB Securities are acting as joint book-running managers for this offering.

Oculis Announces Launch of Proposed Public Offering of Ordinary Shares

Retrieved on: 
Tuesday, May 30, 2023
Attention, Diabetic retinopathy, Telephone, BofA Securities, OCS, Arctica Finance, Sale, Prospectus, State Street, SVB, Form, Pecten oculi, SVB Securities, Pareto, Life insurance, Security (finance)

ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the launch of a follow-on public offering of 5,000,000 ordinary shares.

Key Points: 
  • ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the launch of a follow-on public offering of 5,000,000 ordinary shares.
  • In addition, Oculis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of ordinary shares to be sold in the offering on the same terms and conditions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
  • All of the securities in the offering are to be sold by Oculis.

Oculis Co-founders Selected as Finalists in European Inventor Award 2023

Retrieved on: 
Thursday, May 11, 2023
Retina, DME, Eye, European Patent Office, Quality of life, OCS, Research, Diabetic retinopathy, Inflammation, Solubility, Dexamethasone, Invention, Pain, Patient, European, Ophthalmology, European Patent Convention, European Inventor Award, Pharmaceutical industry, Film industry, Pecten oculi

The European Inventor Award is one of Europe's most prestigious innovation prizes.

Key Points: 
  • The European Inventor Award is one of Europe's most prestigious innovation prizes.
  • Launched by the European Patent Office in 2006, the award honours individuals and teams who have come up with solutions to some of the biggest challenges of our time.
  • Professors Stefánsson and Loftsson, who co-founded Oculis, have been nominated in recognition of their research developing Oculis’ OPTIREACH solubilizing formulation technology.
  • Riad Sherif, M.D., CEO of Oculis, said: “I’m delighted that Einar’s and Thorsteinn’s research has been recognised by the European Patent Office.